Antidote's EU Green Light Brightens Pradaxa Sales Outlook
This article was originally published in Scrip
The positive opinion granted by the European Medicines Agency to a reversal agent that is expected to be used very rarely brings Boehringer Ingelheim one step closer to a potential healthy injection of additional sales for its anticoagulant Pradaxa (dabigatran). Datamonitor Healthcare predicts that Pradaxa revenues in the EU could rise by 15% by 2020, should the Pradaxa antidote Praxbind (idarucizumab) be approved this year. This is now expected following the positive recommendation from the EMA's Committee for Medicinal Products for Human Use (CHMP).
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.